Koers Roche Holding AG Xetra
Aandelen
RHO5
CH0012032048
Farmaceutische producten
Omzet 2024 * | 60,04 mld. 65,65 mld. 61,39 mld. | Omzet 2025 * | 63,83 mld. 69,8 mld. 65,27 mld. | Marktkapitalisatie | 178 mld. 195 mld. 182 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 13,31 mld. 14,56 mld. 13,61 mld. | Nettowinst (verlies) 2025 * | 14,75 mld. 16,13 mld. 15,08 mld. | EV/omzet 2024 * | 3,21 x |
Nettoschuld 2024 * | 14,24 mld. 15,57 mld. 14,56 mld. | Nettoschuld 2025 * | 8,17 mld. 8,93 mld. 8,35 mld. | EV/omzet 2025 * | 2,92 x |
K/w-verhouding 2024 * |
13
x | K/w-verhouding 2025 * |
11,8
x | Werknemers | 103.605 |
Dividendrendement 2024 * |
4,4% | Dividendrendement 2025 * |
4,55% | Vrij verhandelbaar | 88,91% |
Recentste transcriptie over Roche Holding AG
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 49 | 01-01-03 | |
Severin Schwan
CHM | Chairman | 57 | 01-01-08 |
Alan Hippe
DFI | Director of Finance/CFO | 57 | 01-04-11 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Bernard Poussot
BRD | Director/Board Member | 72 | 03-03-15 |
Director/Board Member | 59 | - | |
Director/Board Member | 65 | 01-01-96 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,83% | 661 mld. | |
+27,00% | 566 mld. | |
-6,76% | 352 mld. | |
+20,34% | 332 mld. | |
+3,00% | 283 mld. | |
+13,09% | 231 mld. | |
+5,46% | 200 mld. | |
-6,26% | 145 mld. | |
-11,77% | 144 mld. |